Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Professor Alfred Zippelius to discuss his research.
Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Professor Ignacio Melero to discuss his research.
Tumour cells escaping the immune system is a major cause of resistance to cancer immunotherapy. So how can we stop it? Audrey G\u00e9rard sat down with CRUK to discuss...
Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Professor Felipe Galvez-Cancino, who has recently joined the Nuffield Department of Medicine, to discuss his research.
Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to apply Oxford's leading expertise in fundamental immunology to enable more patients, with a wide range of cancer types, to benefit safely from tailored immunotherapy use. We sat down with Professor David Withers, who recently moved to Oxford, to discuss his research.
Giamp Valenzano, a DPhil in Cancer Science student, joins forces with Oxford Sparks to deliver a video explaining how his research on immunotherapy aims to help treat cancer
Scientists have discovered the key features of immune B cells which make them successful at targeting tumours \u2013 including when cancer has spread to a different part of the body.
The immune system in the intestine maintains a careful balance, tolerating our long-term resident (commensal) gut bacteria while defending against invading pathogens. Under certain circumstances, dysregulation of our intestinal immune response to commensal and pathogenic microbes can drive inflammatory disease.
Through the Oxford Cancer Immuno-Oncology Network (OCION), we aim to realise the long-term curative benefits of immunotherapy for more patients by devising new treatments, broadening the impact of existing treatments, and reducing side effects. We sat down with Director, Tim Elliott, to discuss further.
Oxford and UCL researchers seeking to create the world\u2019s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to \u00a31.7 million from Cancer Research UK and the CRIS Cancer Foundation.
The mission of the Oxford Cancer Immuno-Oncology Network (OCION) Funding Scheme is to pump-prime innovative Oxford-based immuno-oncology research and build capacity in cancer immunology. We sat down with 2023 awardee, Alistair Easton, to discuss what research the fund will enable him to carry out.
Audrey G\u00e9rard has received \u00a3 1.5 million in funding from CRUK for a new research project to unravel the coevolving cancer and immune landscape.
New research has uncovered how antibodies trigger immune receptors in T cells. This breakthrough provides an improved framework for designing therapeutic antibodies, which could be used in new and better therapies for cancer and autoimmune diseases.
The largest multiparameter immunoprofiling study in cancer to date has suggested an underappreciated role of a subset of immune cells in determining the risk of bowel cancer relapse after surgery.
The mission of the Oxford Cancer Immuno-Oncology Network (OCION) Funding Scheme is to pump-prime innovative Oxford-based immuno-oncology research and build capacity in cancer immunology. We sat down with 2023 awardee, Kim Midwood, to discuss what research the fund will enable her to carry out.
The first patient in Oxfordshire has been treated in an mRNA cancer vaccine trial at Oxford University Hospitals NHS Foundation trust (OUH). The trial, led locally by Dr Ketan Shah, consultant clinical oncologist at OUH, marks a significant milestone in the national cancer vaccine advance.
A team of Oxford researchers has discovered a link between immune cells known as monocytes in tumours and overall survival in patients with oesophageal cancer.
We were delighted to officially launch our Oxford Cancer Immuno-Oncology Network on the 23rd of June, with over 100 people in attendance and the luxury of convening at the Ashmolean Museum.
![\"\"](\"https://www.cancer.ox.ac.uk/news/ocion-in-conversation-with-alfred-zippelius/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n